237 related articles for article (PubMed ID: 30672165)
1. Prognostic Significance for Long-Term Outcomes Following Radical Prostatectomy in Men with Prostate Cancer: Evaluation with Prostate Imaging Reporting and Data System Version 2.
Kim R; Kim CK; Park JJ; Kim JH; Seo SI; Jeon SS; Lee HM
Korean J Radiol; 2019 Feb; 20(2):256-264. PubMed ID: 30672165
[TBL] [Abstract][Full Text] [Related]
2. Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers: initial results.
Park SY; Oh YT; Jung DC; Cho NH; Choi YD; Rha KH; Hong SJ
Eur Radiol; 2016 Aug; 26(8):2502-9. PubMed ID: 26560721
[TBL] [Abstract][Full Text] [Related]
3. Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy.
Takeuchi N; Sakamoto S; Nishiyama A; Horikoshi T; Yamada Y; Iizuka J; Maimaiti M; Imamura Y; Kawamura K; Imamoto T; Komiya A; Ikehara Y; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2018 Aug; 16(4):e817-e829. PubMed ID: 29576444
[TBL] [Abstract][Full Text] [Related]
4. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
[TBL] [Abstract][Full Text] [Related]
5. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.
Luzzago S; Musi G; Catellani M; Russo A; Di Trapani E; Mistretta FA; Bianchi R; Cozzi G; Conti A; Pricolo P; Ferro M; Matei DV; Mirone V; Petralia G; de Cobelli O
Urol Int; 2018; 101(1):56-64. PubMed ID: 29734177
[TBL] [Abstract][Full Text] [Related]
7. Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?
Hoffmann R; Logan C; O'Callaghan M; Gormly K; Chan K; Foreman D
Int Urol Nephrol; 2018 Jan; 50(1):13-19. PubMed ID: 29188489
[TBL] [Abstract][Full Text] [Related]
8. Preoperative PI-RADS v2.1 Scoring System Improves Risk Classification in Patients Undergoing Radical Prostatectomy.
Fukui Y; Yamada Y; Sakamoto S; Horikoshi T; Zhao X; Sato K; Nanba S; Kubota Y; Kanesaka M; Fujimoto A; Shibata H; Goto Y; Sazuka T; Imamura Y; Uno T; Ichikawa T
Anticancer Res; 2023 Dec; 43(12):5705-5712. PubMed ID: 38030183
[TBL] [Abstract][Full Text] [Related]
9. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
Tan N; Shen L; Khoshnoodi P; Alcalá HE; Yu W; Hsu W; Reiter RE; Lu DY; Raman SS
J Urol; 2018 May; 199(5):1218-1223. PubMed ID: 29128577
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of relationships between the final Gleason score, PI-RADS v2 score, ADC value, PSA level, and tumor diameter in patients that underwent radical prostatectomy due to prostate cancer.
Gündoğdu E; Emekli E; Kebapçı M
Radiol Med; 2020 Sep; 125(9):827-837. PubMed ID: 32266690
[TBL] [Abstract][Full Text] [Related]
11. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.
Zhai L; Fan Y; Sun S; Wang H; Meng Y; Hu S; Wang X; Yu W; Jin J
Scand J Urol; 2018; 52(5-6):333-339. PubMed ID: 30895901
[TBL] [Abstract][Full Text] [Related]
12. Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance.
Curci NE; Lane BR; Shankar PR; Noyes SL; Moriarity AK; Kubat A; Brede C; Montgomery JS; Auffenberg GB; Miller DC; Montie JE; George AK; Davenport MS
Urology; 2018 Jun; 116():137-143. PubMed ID: 29653121
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Accuracy Study of Prostate Imaging Reporting and Data System Version 2 on Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer With Whole-mount Pathology.
Giannarini G; Girometti R; Crestani A; Rossanese M; Calandriello M; Cereser L; Bednarova S; Battistella C; Sioletic S; Zuiani C; Valotto C; Ficarra V
Urology; 2019 Jan; 123():191-197. PubMed ID: 30273613
[TBL] [Abstract][Full Text] [Related]
14. Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.
Sharma V; Nehra A; Colicchia M; Westerman ME; Kawashima A; Froemming AT; Kwon ED; Mynderse LA; Karnes RJ
Eur Urol; 2018 Jun; 73(6):879-887. PubMed ID: 29195777
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Rajwa P; Mori K; Huebner NA; Martin DT; Sprenkle PC; Weinreb JC; Ploussard G; Pradere B; Shariat SF; Leapman MS
J Urol; 2021 Sep; 206(3):507-516. PubMed ID: 33904755
[TBL] [Abstract][Full Text] [Related]
16. Utility of Multiparametric Magnetic Resonance Imaging With PI-RADS, Version 2, in Patients With Prostate Cancer Eligible for Active Surveillance: Which Radiologic Characteristics Can Predict Unfavorable Disease?
Kim H; Pak S; Park KJ; Kim MH; Kim JK; Kim M; You D; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
Clin Genitourin Cancer; 2020 Feb; 18(1):50-55. PubMed ID: 31640913
[TBL] [Abstract][Full Text] [Related]
17. Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.
Morris DS; Woods JS; Edwards B; Lenz L; Logan J; Flake DD; Mabey B; Bishoff JT; Cohen T; Stone S
Urol Oncol; 2021 Jun; 39(6):366.e19-366.e28. PubMed ID: 33257218
[TBL] [Abstract][Full Text] [Related]
18. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
[TBL] [Abstract][Full Text] [Related]
19. Magnetic Resonance Imaging-based T-staging to Predict Biochemical Recurrence after Radical Prostatectomy: A Step Towards the iTNM Classification.
Baboudjian M; Gondran-Tellier B; Touzani A; Martini A; Diamand R; Roche JB; Lacetera V; Beauval JB; Roumeguère T; Simone G; Benamran D; Fourcade A; Fiard G; van den Bergh RCN; Peltier A; Ploussard G
Eur Urol Oncol; 2023 Aug; 6(4):406-413. PubMed ID: 36280445
[TBL] [Abstract][Full Text] [Related]
20. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
